Cargando…
Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A
Afatinib has anti-tumor effect in non-small cell lung carcinoma (NSCLC) with epidermal growth factor receptor (EGFR) mutation. We found afatinib can also induce apoptosis in NSCLC cells without EGFR mutation through CIP2A pathway. Four NSCLC cell lines (H358 H441 H460 and A549) were treated with afa...
Autores principales: | Chao, Ting-Ting, Wang, Cheng-Yi, Chen, Yen-Lin, Lai, Chih-Cheng, Chang, Fang-Yu, Tsai, Yi-Ting, Chao, Chung-Hao H., Shiau, Chung-Wai, Huang, Yuh-Chin T., Yu, Chong-Jen, Chen, Kuen-Feng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385843/ https://www.ncbi.nlm.nih.gov/pubmed/25537503 |
Ejemplares similares
-
Bortezomib Congeners Induce Apoptosis of Hepatocellular Carcinoma via CIP2A Inhibition
por: Hou, Duen-Ren, et al.
Publicado: (2013) -
CIP2A is a target of bortezomib in human triple negative breast cancer cells
por: Tseng, Ling-Ming, et al.
Publicado: (2012) -
Comprehensive assessment of pretreatment sarcopenia impacts on patients with
EGFR
‐mutated NSCLC treated with afatinib
por: Wu, Chen‐Te, et al.
Publicado: (2023) -
SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A
por: Hung, Man-Hsin, et al.
Publicado: (2015) -
Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
por: Jiang, Yingying, et al.
Publicado: (2023)